8 source-based articles maintained by the HealthRX.com Editorial Team.
Showing 8 of 8 clinical reviews.
A detailed breakdown of the enrollment biases, attrition problems, generalizability gaps, statistical caveats, and conflict-of-interest concerns in the landmark Olsen finasteride 5-year hair-loss study.
A detailed methodology breakdown of the Olsen et al. 2002 finasteride 1 mg trial, examining randomization design, endpoint definitions, statistical approach, and how each choice shapes interpretation of 5-year AGA hair count data.
Deep-dive into the Olsen 2002 finasteride 5-year extension study: durability of hair count gains, regression patterns after discontinuation, long-term safety signals, and clinical implications for AGA treatment planning.
A deep dive into the primary and secondary endpoint results from the Olsen et al. 5-year finasteride 1 mg trial for androgenetic alopecia, including hair count trajectories, response distributions, and vertex vs frontal data.
A review of the pre-specified and post-hoc subgroup analyses from the Olsen et al. 5-year finasteride 1 mg trial, examining response patterns by age, vertex vs frontal location, baseline hair count, and other clinical variables, with an honest accounting of which specific effect sizes require verification against the primary publication.
A deep-dive into the landmark 5-year finasteride 1 mg trial for androgenetic alopecia, covering methodology, results, limitations, and clinical relevance.
A deep-dive into the economic modeling, cost-per-QALY estimates, payer-coverage realities, and individual relative-value calculations derived from the Olsen et al. 2002 five-year finasteride trial in androgenetic alopecia.
How the Olsen 2002 five-year finasteride trial reshaped prescribing for androgenetic alopecia, which guidelines it influenced, and what it means for patients outside the original study population.